In its January 2026 report, Solid Biosciences shared an update on SGT-003, our investigational next-generation gene therapy for Duchenne muscular dystrophy. We have provided a summary of the trial updates below, accompanied by Solid Biosciences community letter for further reading.
INSPIRE DUCHENNE
This is an ongoing phase 1/2 study designed to evaluate the safety and effectiveness of SGT-003 in children aged 1 to 10.
- Dosing Milestone: As of early January 2026, 33 participants have been dosed in this trial.
- Where is it happening?: The US, Canada, the UK and Italy.
- Safety Update: Solid reported that the therapy has been generally well tolerated. Importantly, they are using a steroid-only approach to manage the immune system after dosing, which is a simpler regimen than some other gene therapies.
- Encouraging Results: To date, there have been no reports of serious liver or heart complications (such as DILI or myocarditis). Additionally, early data shows encouraging levels of microdystrophin expression and improvements in markers that indicate better muscle health.
- Heart Health: Researchers have observed signals that the therapy may be helping to normalise markers of cardiac (heart) injury, which is a vital area of focus for the Duchenne community.
IMPACT DUCHENNE
While the INSPIRE study continues, Solid is moving forward with a larger, global Phase 3 study called IMPACT DUCHENNE. This study is randomised and double-blind, meaning some participants will receive a placebo initially to help demonstrate the drug’s effectiveness.
- Global Expansion: This study is being conducted outside of the United States.
- Current Status: The first participant has already been enrolled with dosing expected in Q1 of 2026.
- Where is it happening? The first clinical sites are currently active in Canada and Australia.
- Europe and the UK: Solid plans to expand this study into European countries starting in mid-2026, subject to regulatory approvals.
Entrada Therapeutics: 2026 Clinical Trial Plan & Progress
